药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Difenoxin
Troleandomycin
The risk or severity of adverse effects can be increased when Troleandomycin is combined with Polatuzumab vedotin.
Difenoxin
Danoprevir
The risk or severity of adverse effects can be increased when Danoprevir is combined with Polatuzumab vedotin.
Difenoxin
Ribociclib
The risk or severity of adverse effects can be increased when Ribociclib is combined with Polatuzumab vedotin.
Difenoxin
Stiripentol
The risk or severity of adverse effects can be increased when Stiripentol is combined with Polatuzumab vedotin.
Difenoxin
Elvitegravir
The risk or severity of adverse effects can be increased when Elvitegravir is combined with Polatuzumab vedotin.
Difenoxin
Midostaurin
The risk or severity of adverse effects can be increased when Midostaurin is combined with Polatuzumab vedotin.
Difenoxin
Ditiocarb
The risk or severity of adverse effects can be increased when Ditiocarb is combined with Polatuzumab vedotin.
Difenoxin
Metreleptin
The metabolism of Polatuzumab vedotin can be increased when combined with Metreleptin.
Difenoxin
Belantamab mafodotin
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Belantamab mafodotin.
Difenoxin
Odesivimab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Odesivimab.
Difenoxin
Maftivimab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Maftivimab.
Difenoxin
Atoltivimab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Atoltivimab.
Difenoxin
Zenocutuzumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Zenocutuzumab.
Difenoxin
Emapalumab
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Emapalumab.
Difenoxin
Mirvetuximab Soravtansine
The risk or severity of adverse effects can be increased when Polatuzumab vedotin is combined with Mirvetuximab Soravtansine.
Difenoxin
Lorvotuzumab mertansine
The risk or severity of adverse effects can be increased when Lorvotuzumab mertansine is combined with Polatuzumab vedotin.
Difenoxin
Sarilumab
The risk or severity of adverse effects can be increased when Sarilumab is combined with Polatuzumab vedotin.
Difenoxin
Siltuximab
The risk or severity of adverse effects can be increased when Siltuximab is combined with Polatuzumab vedotin.
Difenoxin
Secukinumab
The risk or severity of adverse effects can be increased when Secukinumab is combined with Polatuzumab vedotin.
Difenoxin
Certolizumab pegol
The risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Polatuzumab vedotin.